MYNZ News & Events

Mainz Biomed reviewed its major accomplishments for the year ended December 31, 2025. "I'm extremely pleased with the achievements of our team during 2025 as we advance our ambitious growth strategy, driven by our eAArly DETECT 2 study and continued progress in our pancreatic cancer screening program," commented Guido Baechler, CEO of Mainz Biomed. "Looking ahead to the first half of 2026, we expect to complete our eAArly DETECT 2 feasibility study, which will be the launching point for our ReconAAsense US FDA pivotal colorectal cancer study in 2026, and to announce our next steps in advancing our blood-based screening test for the early detection of pancreatic cancer."

Mainz Biomed files $150M mixed securities shelf

Mainz Biomed announced that its test ColoAlert has been added to the portfolio of DoctorBox. This marks another important milestone in Mainz Biomed's European growth strategy and highlights the increasing importance of innovative, personalized solutions in preventive medicine. Laboratory analysis will be performed by Mainz Biomed's long-standing partner, the European Oncology Lab, led by Dr. med. Annette Buhlmann in St. Ingbert, Germany.

Mainz Biomed announced the signing of a Memorandum of Understanding, MOU, with OncoVanguard8, a distributor of oncological innovations. The collaboration aims to introduce ColoAlert, a DNA-based colorectal cancer, CRC, screening test, to South America, starting with Peru.